including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, and innovations in products and technologies will redefine the next generation of radiopharmaceuticals
View more
NorthStar is poised to be the first commercial-scale producer of rare radioisotope, in chronic short supply, for use in clinical studies and patient healthcare to treat many types of cancer
View moreFAPI-PET shows promise in patients with RA
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
PET AI model improves lung cancer staging
MD Anderson, Radiopharm Theranostics Join Forces on Therapeutic Radiopharmaceuticals
MONOPAR AND NORTHSTAR ANNOUNCE EXPANDED RADIOPHARMA PROGRAM, POSITIVE PRECLINICAL RESULTS, AND VISIBILITY TOWARD HUMAN TRIALS
Nuclear medicine outlook:proven molybdenum-99 supply chain reliability and new planned capacity continue to benefit patients
